Danhke Weekly Report 20180610: Overview of the 2018 Primary Healthcare Innovation Summit Hosted by VB Insights

Monday |Seven Medical AI Companies Enter the First Affiliated Hospital of Chongqing Medical University; Its Radiology Department Director States That Medical Imaging AI Should Focus on Serving Clinicians

Medical AI companies must take responsibility for their products deployed in hospitals and strengthen communication with physicians.

Tuesday |Leveraging National Power to “Knock Off” and Greenlighting “Infringement”: How India Turned Generic Drugs into a Nearly $50 Billion Business?

India did not stop at simple generic replication; instead, it established a set of drug manufacturing standards aligned with regulatory frameworks in Europe and the United States, thereby laying the groundwork for industrial upgrading.

China’s pharmaceutical industry has followed a similar trajectory, evolving from generic drugs to an integrated approach of prevention and innovation, and ultimately achieving “overtaking on the bend” in the biopharmaceutical sector. Bolstered by favorable policies, capital influx, and market dynamics, China’s domestic pharmaceutical industry still has a long journey ahead.

Wednesday |After Investing in Donghua Software and Winning Health, Tencent and Alibaba Finally Gain a Foothold in the Industry

A week after Tencent announced a RMB 1.266 billion capital injection into Donghua Chengxin, acquiring a 5% stake in Donghua Software, Alibaba has also made its move by partnering with Winning Health, another giant in healthcare informatics. The equity transfer in Winning Health is expected to reach 5% or more (including 5%), but the transaction will not involve a change in corporate control.

Thursday |Survey Report on the Use of Mobile Health Apps by Physicians: Doctors’ Needs Demonstrate “Pragmatism,” with Utility-Based Apps Poised to Emerge as the Biggest Winners

The development of mobile health apps has evolved from a broad to a focused approach, and from top-down implementation to continuous refinement and deepening. Representative tool-based apps will find growth opportunities as physicians’ latent needs become increasingly prominent. For physicians, well-designed product logic in tool-based apps can deliver tangible efficiency gains in daily clinical practice. Consequently, the role of mobile health apps will shift from being merely connectivity platforms and knowledge gateways to serving as work assistants and efficiency tools.

Friday |Internet Healthcare: The True Dream

We believe that industry development follows its own inherent laws. In the face of the sweeping emergence of new developments, the fluctuations and adjustments in policy are inevitable experiences. Policymakers, being human themselves, also require extensive experience and observation before they can make firm decisions.

Saturday |Restructuring Healthcare Production Relations to Unlock New Business Opportunities—Report on the Commercial Value of Medical Consortia

The future healthcare management model features industrial alliances as the primary governing entities, achieving front-end governance of the healthcare system through a combination of market mechanisms and alliance agreements. Government functions will shift from initial front-end governance to systemic oversight. For healthcare resources, mobility will increase significantly. Due to changes in competitive dynamics, the boundaries of resource flow will expand from within individual institutions to across the entire industry, thereby substantially improving the rationality of resource allocation and utilization efficiency.

Li Keqiang, Member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, conducted an inspection in Yinchuan City, accompanied by Shi Taifeng, Secretary of the Party Committee of Ningxia Hui Autonomous Region, and Xian Hui, Chairman of the Autonomous Region. The Premier visited Yinchuan First People’s Hospital, Minning Middle School, and the iBi Incubation Center to gain insights into the application of “Internet Plus” across various sectors. He stated that leveraging “Internet Plus” holds immense potential for improving key areas of public welfare. He expressed his hope that Ningxia would take the lead in establishing a demonstration zone for “Internet Plus Healthcare,” thereby benefiting people of all ethnic groups as well as surrounding regions, with active support from the state.

Keywords: Internet + Medical Health, Yinchuan

CStone Pharmaceuticals and Blueprint Medicines Announce Exclusive Collaboration and License Agreement to Advance the Clinical Development and Commercialization of Avapritinib, BLU-554, and BLU-667 as Monotherapies or in Combination Therapies in Mainland China, Hong Kong, Macau, and Taiwan

Keywords: Pharmaceutical; Collaboration

Shanghai Electric Group Co., Ltd. announced the establishment of a RMB 1.6 billion medical device M&A fund in partnership with Lianchuang Yongjun, a well-established private equity firm. The fund will primarily invest in medical equipment and devices, including but not limited to in vitro diagnostics, radiation therapy, medical imaging, ultrasound equipment, medical robots, healthcare services, rehabilitation medicine, and home medical devices.

KeyKeywords: Internet + Healthcare, Yinchuan

Winning Health announced that Shanghai Yunxin, a subsidiary of Ant Financial under Alibaba Group, plans to acquire a 5% stake in Winning Health. It is understood that both parties will further engage in deep and comprehensive cooperation by leveraging Winning Health’s resources, capabilities, and practices in the broader healthcare sector, combined with the resources and capabilities of Yunxin and its affiliates.

Keywords: Acquisition

Major Investment Project of the Jinan International Medical Science Center—The Shandong Innovation Center of the National Human Genetic Resources Sharing Service Platform Has Passed the Comprehensive Evaluation and Acceptance by the Expert Assessment Team of the Ministry of Science and Technology. Upon completion, it will be centered in Shandong, radiating to surrounding provinces and municipalities, sharing national resources in science and technology, healthcare, and hospital-enterprise collaborations, and gradually integrating regional biobanks of typical population samples and large-scale medical health databases.

Keywords: Jinan, Medical Big Data

CCTV Finance Channel, in its series “Seeking True Growth in the Pharmaceutical Industry,” focused its coverage on the pharmaceutical distribution sector in Henan Province. Using Henan as a cross-sectional case study, it produced a special report titled “Accelerated Mergers and Acquisitions Reshape the Pharmaceutical Distribution Industry.” As of the end of 2017, there were 303 pharmaceutical logistics and wholesale enterprises in Henan; to date, only slightly more than 210 remain.

Keywords: Pharmaceutical Distribution

Frontier Biotechnologies, Inc. (Nanjing) announced today that its independently developed Class 1 new drug, Aikening® (albuvirtide for injection), has been approved for marketing by the National Medical Products Administration. Aikening® is the world’s first long-acting HIV-1 fusion inhibitor and China’s first original anti-HIV new drug. It was successfully developed independently by Frontier Biotechnologies and holds global intellectual property rights.

Keywords: Pharmaceutical Distribution

QuanYao.com issued the “Notice on Publicizing Price Reductions for Selected Items in the Shenzhen Public Hospital Group Procurement Drug Catalog,” resulting in price reductions for 30 drugs. These price adjustments were made by the group procurement organization in response to changes in market prices.

Keywords: Pharmaceutical Distribution

Internationally Leading One-Stop Biopharmaceutical CDMO Service Platform, WuXi XDC (Suzhou) Co., Ltd. Announces Strategic Cooperation Agreement with Akeso Biopharma (Suzhou) Co., Ltd. Both parties will fully leverage their respective strengths in custom development and manufacturing of biologics (CDMO) and international R&D of innovative ADC drugs.

Keywords: Pharmaceutical Distribution

June 6 marked the 23rd National Eye Care Day. The National Health Commission held a special press conference to introduce scientific measures for myopia prevention and control among children and adolescents, as well as three newly released guidelines: the Guidelines for Myopia Prevention and Treatment, the Guidelines for Diagnosis and Treatment of Amblyopia, and the Guidelines for Diagnosis and Treatment of Strabismus.

Keywords: Myopia

Tasly Holding Group Co., Ltd. and Shenzhen Tencent Computer Systems Co., Ltd. have signed a strategic cooperation agreement to jointly advance the development of smart healthcare systems. The two parties will collaborate on innovating, establishing, and implementing models and implementation plans for smart pharmaceutical manufacturing, smart medical insurance, smart healthcare, smart chronic disease management, smart central city pharmacies, and smart traceability. By co-building platforms and engaging in joint operations, they aim to cooperate in areas such as big data analytics in pharmaceuticals, separation of prescribing and dispensing, decentralization of medical resources, precision chronic disease management, rational cost control in medical insurance, and precise patient monitoring.

Keywords: Pharmaceuticals, Medical Insurance, Chronic Diseases

At the first 2018 meeting of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) held in Kobe, Japan, China’s National Medical Products Administration was elected as a member of the ICH Management Committee.

Keywords: ICH

Pharmaceutical company Biogen announced that it has entered into an exclusive option agreement with Japan’s TMS Corporation for the acquisition of the latter’s drug candidate TMS-007 and other backup compounds. The agreement includes an upfront payment of $4 million, with an additional $18 million payable upon Biogen’s exercise of the option. Potential development and commercialization milestones, along with tiered royalties, could bring the total value of the transaction to up to $335 million.

Keywords: Biogen

Late on June 7, the official website of the Guangdong Provincial Drug Exchange Center released the “Notice on Doing a Good Job in the Implementation of the ‘Two-Invoice System’ for Drug Transactions by Medical Institutions in Our Province” (hereinafter referred to as the “Notice”), marking the long-awaited final implementation of Guangdong’s “Two-Invoice System” in the pharmaceutical sector.

Keywords: Guangdong Province, Two-Invoice System

This week, there were 11 financing events in the medical field both domestically and internationally.

The safest approach for investors is to observe until entrepreneurs have truly fallen into the pitfalls they were destined to encounter and managed to climb out, and have stumbled where they were bound to trip. Only then does the entire team mature, developing rational thinking, selecting from a diverse arsenal of skills the one best suited to them, and thereby establishing their own business model and distinct competitive advantages. (Source: Health界)

On June 4, NYU Langone Health launched its digital children’s hospital. Patients can use the MyWall platform on their tablets to access information about their care teams and treatment plans. The platform also enables patients to handle practical tasks, such as ordering meals and adjusting room ambiance, allowing them to truly experience digital integration in their daily lives. This state-of-the-art technology suite has been meticulously designed to enhance staff efficiency, maximize patient safety, and provide a more personalized experience for patients and their families. (Source: mobihealthnews.com)

On June 5, Apple released the Health Records API, enabling developers to create applications that leverage patients’ electronic health record (EHR) data to help individuals manage their health needs. With the new Health Records API, physicians can integrate patients’ medical data into their ResearchKit study apps, thereby gaining a more comprehensive understanding of participants’ health backgrounds. Furthermore, with participants’ consent, researchers can access specific patient information to ensure more thorough research. (Source: healthcareitnews.com)

This week, a latest study by Coyne Scientific offers a novel strategy to accelerate drug development—Clinical Trials in a Dish (CTiD)—which bridges preclinical studies and clinical trials. Researchers argue that the high attrition rate in clinical development necessitates establishing a research bridge between preclinical stages and clinical trials, enabling earlier decisions on whether to continue or halt drug development. CTiD optimizes the drug development process for entry into clinical development, reduces resource consumption, and expedites the delivery of safe medications that meet medical needs to patients. (Source: genengnews.com)

This report provides an in-depth analysis of the current application status, industry chain, and typical corporate case studies of big data in the healthcare sector. It also explores the development trends of healthcare big data, with the aim of serving as a reference for market stakeholders to gain a deeper understanding of this field.

This report begins with policy analysis to provide an in-depth examination of the new directions in informatization driven by policy reforms.

This report analyzes the opportunities and challenges in China’s health supplement market and proposes development strategies for relevant enterprises. Driven by factors such as consumption upgrading and favorable policies, the market size is projected to grow from approximately RMB 120 billion in 2015 to around RMB 180 billion in 2020, surpassing the United States to become the world’s largest in the foreseeable future. To capitalize on market dividends while navigating stringent regulatory requirements, companies must prepare strategically in three key areas: product/branding, distribution channels, and international cooperation.

With the release of the “Outline of the Healthy China 2030 Plan” and the deepening of healthcare reform policies, implementing the Healthy China strategy has become the guiding framework for health and hygiene work in the new era. As multiple cost-containment healthcare reform measures are gradually implemented, the next phase of focus for China’s medical services industry will be to balance medical resources across multiple dimensions and fully promote a tiered diagnosis and treatment system. Meanwhile, while ensuring basic medical services for all citizens, efforts will be made to foster the development of diversified and personalized medical services, encouraging market-oriented innovation in healthcare delivery.

For more content, please visit the VCBeat Knowledge Base!